UB Paderborn / Katalog / Suche / in CDI

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

The New England journal of medicine, 2017-10, Vol.377 (15), p.1438-1447

2017

Volltextzugriff (PDF)

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

PloS one, 2016-05, Vol.11 (5), p.e0155100-e0155100

2016

Volltextzugriff (PDF)

Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves

Current opinion in HIV & AIDS, 2010-11, Vol.5 (6), p.473

2010

Volltextzugriff (PDF)

How to construct an optimal interim report: What the data monitoring committee does and doesn’t need to know

Clinical trials (London, England), 2018-08, Vol.15 (4), p.359-365

2018

Volltextzugriff (PDF)

Health Utility Estimates and Their Application to HIV Prevention in the United States: Implications for Cost-Effectiveness Modeling and Future Research Needs

MDM policy & practice, 2020-07, Vol.5 (2), p.238146832093621-2381468320936219

2020

Volltextzugriff (PDF)

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The New England journal of medicine, 2015-08, Vol.373 (9), p.795-807

2015

Volltextzugriff (PDF)

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

The New England journal of medicine, 2021-03, Vol.384 (10), p.905-914

2021

Volltextzugriff (PDF)

Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site

Obesity (Silver Spring, Md.), 2007-06, Vol.15 (6), p.1441-1447

2007

Volltextzugriff (PDF)

Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection

The Journal of infectious diseases, 2016-08, Vol.214 (3), p.408-416

2016

Volltextzugriff (PDF)

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

The Lancet (British edition), 2022-02, Vol.399 (10324), p.530-540

2022

Volltextzugriff (PDF)

Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection

AIDS (London), 2017-04, Vol.31 (7), p.953-963

2017

Volltextzugriff (PDF)

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Annals of internal medicine, 2021-01, Vol.174 (1), p.93

2021

Volltextzugriff (PDF)

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

AIDS (London), 2008-09, Vol.22 (14), p.F17-F24

Lundgren, J D

2008

Volltextzugriff (PDF)

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

The lancet respiratory medicine, 2022-10, Vol.10 (10), p.972-984

2022

Volltextzugriff (PDF)

Randomized Trial of Vaccines for Zaire Ebola Virus Disease

The New England journal of medicine, 2022-12, Vol.387 (26), p.2411-2424

2022

Volltextzugriff (PDF)

Interim monitoring in a treatment strategy trial with a composite primary endpoint

Contemporary clinical trials, 2019-11, Vol.86, p.105846-105846, Article 105846

2019

Volltextzugriff (PDF)

Continuous antiretroviral therapy decreases bone mineral density

AIDS (London), 2009-07, Vol.23 (12), p.1519-1529

2009

Volltextzugriff (PDF)

Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV

AIDS (London), 2023-03, Vol.37 (3), p.379-387

2023

Volltextzugriff (PDF)

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

Journal of bone and mineral research, 2017-09, Vol.32 (9), p.1945-1955

2017

Volltextzugriff (PDF)

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

American journal of respiratory and critical care medicine, 2022-09, Vol.206 (6), p.730-739

2022

Volltextzugriff (PDF)

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

Clinical infectious diseases, 2018-07, Vol.67 (3), p.420-429

2018

Volltextzugriff (PDF)

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV medicine, 2015-04, Vol.16 (S1), p.137-146

2015

Volltextzugriff (PDF)

LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply

The lancet HIV, 2018-05, Vol.5 (5), p.e206-e206

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves

How to construct an optimal interim report: What the data monitoring committee does and doesn’t need to know

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

Health Utility Estimates and Their Application to HIV Prevention in the United States: Implications for Cost-Effectiveness Modeling and Future Research Needs

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site

Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Randomized Trial of Vaccines for Zaire Ebola Virus Disease

Interim monitoring in a treatment strategy trial with a composite primary endpoint

Continuous antiretroviral therapy decreases bone mineral density

Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial

Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply

Suchergebnisse filtern